| abstract |
Provided are a genome editing system CRISPR-C2c1 for site-directed modification of a target sequence in a cell genome and use thereof, the system comprising a C2c1 protein or a variant thereof and a guide RNA. Also provided are a method for site-directed modification of a target sequence in a cell genome using the genome editing system CRISPR-C2c1, and a pharmaceutical composition comprising the genome editing system CRISPR-C2c1. |